Answers are grounded in this paper and cite their sources.
mutant lymphomas show increased sensitivity to RapaLink-1, a bifunctional mTOR inhibitor. Hence, SESTRIN1 contributes to the genetic and epigenetic control of mTORC1 in lymphoma and influences responses to targeted therapies.
No takes yet. Share an insight, caveat, or question.
Oricchio et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: